| Objective To investigate the effect of different doses of vitamin D combined with calcium in the prevention of secondary osteoporosis in children nephrotic syndrome. Methods Clinical data of 56 children with nephrotic syndrome who received treatment from January 2021 to June 2023 were collected and divided into group A (18 cases), group B (21 cases) and group C (17 cases) according to treatment methods. On the basis of routine glucocorticoid therapy and nutritional intervention, group A was treated with vitamin D3 (600 IU/d) and calcium carbonate D3 (500 mg/d), group B was treated with vitamin D3 (1000 IU/d) and calcium carbonate D3 (500 mg/d). Group C was treated with vitamin D3 (1200 IU/d) and calcium carbonate D3 (500 mg/d). After 12 months of treatment, calcium and phosphorus metabolism, bone metabolism, nutrition, adverse drug reactions and infection were compared. Results Serum calcium and 25-hydroxyvitamin D3[25- (OH) D3)] : Group A < group B < group C (P<0.05); Parathyroid hormone (PTH) : Group A > group B > group C (P<0.05). Bone alkaline phosphatase (BALP), amino terminal peptide of type I collagen (PINP), C-terminal peptide β degradation product of type I collagen (β-CTX) : group A > group B > group C (P<0.05); Bone mineral density (BMD) : Group A < group B < group C (P<0.05). Albumin (ALB), prealbumin (PALP), total protein (TP) : group A < group B < group C (P<0.05). Comparison of infection rates among Group A, Group B, and Group C (22.22% vs 14.29% vs 11.76%, χ2=0.415, P>0.05). Conclusion Within the dosage range of 600-1200 IU/d, there is a certain dose-response relationship between vitamin D and prevention of secondary osteoporosis in children with nephrotic syndrome. 1200 IU/d vitamin D can better regulate calcium metabolism and bone metabolism, improve the nutritional status of children with nephrotic syndrome, and has good safety. |